Voyager Therapeutics Inc. (NASDAQ: VYGR) stock jumped 1.62% on Wednesday to $5.66 against a previous-day closing price of $5.57. With 0.14 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.16 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $5.92 whereas the lowest price it dropped to was $5.54. The 52-week range on VYGR shows that it touched its highest point at $10.60 and its lowest point at $2.54 during that stretch. It currently has a 1-year price target of $7.60. Beta for the stock currently stands at 0.93.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of VYGR was up-trending over the past week, with a rise of 8.64%, but this was up by 7.20% over a month. Three-month performance dropped to -11.01% while six-month performance fell -5.03%. The stock gained 77.43% in the past year, while it has gained 108.86% so far this year. A look at the trailing 12-month EPS for VYGR yields -0.46 with Next year EPS estimates of -1.95. For the next quarter, that number is -0.59. This implies an EPS growth rate of -292.10% for this year and -62.50% for next year.
Float and Shares Shorts:
At present, 38.51 million VYGR shares are outstanding with a float of 32.93 million shares on hand for trading. On Oct 13, 2022, short shares totaled 0.7 million, which was 1.82% higher than short shares on Sep 14, 2022. In addition to Mr. Robert W. Hesslein as the firm’s Sr. VP & Gen. Counsel, Mr. G. Andre Turenne serves as its Advisor.
Through their ownership of 58.16% of VYGR’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 40.62% of VYGR, in contrast to 35.21% held by mutual funds. Shares owned by individuals account for 11.12%. As the largest shareholder in VYGR with 12.30% of the stake, Ecor1 Capital LLC holds 4,753,907 shares worth 4,753,907. A second-largest stockholder of VYGR, Armistice Capital LLC, holds 3,396,000 shares, controlling over 8.79% of the firm’s shares. The Vanguard Group, Inc. is the third largest shareholder in VYGR, holding 1,887,327 shares or 4.88% stake. With a 2.35% stake in VYGR, the Vanguard Total Stock Market Index is the largest stakeholder. A total of 909,075 shares are owned by the mutual fund manager. The Vanguard Explorer Fund, which owns about 1.18% of VYGR stock, is the second-largest Mutual Fund holder. It holds 457,063 shares valued at 2.37 million. Vanguard Extended Market Index Fu holds 0.95% of the stake in VYGR, owning 366,690 shares worth 1.9 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for VYGR since 7 analysts follow the stock currently. There are 2 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 4 believe that the stock is worth HOLDING, 1 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With VYGR analysts setting a high price target of $10.00 and a low target of $4.00, the average target price over the next 12 months is $8.00. Based on these targets, VYGR could surge 76.68% to reach the target high and fall by -29.33% to reach the target low. Reaching the average price target will result in a growth of 41.34% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. VYGR will report FY 2022 earnings on 03/15/2023. Analysts have provided yearly estimates in a range of -$0.98 being high and -$1.34 being low. For VYGR, this leads to a yearly average estimate of -$1.20. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Voyager Therapeutics Inc. surprised analysts by $0.77 when it reported $0.45 EPS against a consensus estimate of -$0.32. The surprise factor in the prior quarter was -$0.02. Based on analyst estimates, the high estimate for the next quarter is -$0.38 and the low estimate is -$0.75. The average estimate for the next quarter is thus -$0.59.
Summary of Insider Activity:
Insiders traded VYGR stock several times over the past three months with 1 Buys and 2 Sells. In these transactions, 125,000 shares were bought while 349,972 shares were sold. The number of buy transactions has increased to 10 while that of sell transactions has risen to 21 over the past year. The total number of shares bought during that period was 820,468 while 1,013,806 shares were sold.